Drug Profile
Research programme: obesity, diabetes and fatty liver disease therapeutics - Emmyon
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Emmyon
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fatty liver; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Fatty liver in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Obesity in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA